Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002026032 | SCV002292202 | likely pathogenic | Familial melanoma | 2021-07-14 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002407276 | SCV002719283 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-03-21 | criteria provided, single submitter | clinical testing | The c.193G>C pathogenic mutation (also known as p.G65R), located in coding exon 1β of the CDKN2A (p14ARF) gene, results from a G to C substitution at nucleotide position 193. The glycine at codon 65 is replaced by arginine, an amino acid with dissimilar properties. However, this change occurs in the last base pair of coding exon 1β, which makes it likely to have some effect on normal mRNA splicing. This alteration was observed to result in a splice defect utilizing an upstream donor site and an acceptor site in exon 2 which encodes parts of both of the p14 and p16 isoforms of CDKN2A (Harland M et al. Oncogene, 2005 Jun;24:4604-8). This alteration has been observed in many melanoma kindreds (Garcia-Casado Z et al. Melanoma Res. 2009 Oct;19:335-7; Overbeek KA et al. J. Med. Genet. 2020 Jun;: de Torre C et al. Melanoma Res. 2010 Aug;20:342-8; Harland M et al. Hered Cancer Clin Pract. 2014 Nov;12:20; Potjer TP et al. J. Med. Genet. 2018 10;55:661-668; Cust AE et al. J. Med. Genet. 2011 Apr;48:266-72; Goldstein AM et al. Cancer Res. 2006 Oct;66:9818-28). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. This amino acid position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |